In patients with hypertrophic cardiomyopathy, atrial fibrillation is common and associated with high thromboembolic risk, warranting anticoagulation, with LA dimension and age being independent predictors.
AF is common in HCM and associated with high thromboembolic risk. LA dimension and age are independently associated with AF but the literature is insufficient to create robust clinical tools to predict AF or thromboembolism. Most data suggest that AF patients should be anticoagulated.
Guttmann et al. (2013) studied this question.